SCHEMBL25323955

SCHEMBL25323955

OCCCCc1cccc2cccc(Br)c12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.37
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
TAAR1 Q96RJ0 3/20 0.33
ALDH1A1 P00352 2/20 0.33
GAA P10253 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CA2 P00918 2/20 0.32
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C19 P33261 1/20 0.31
HEXA P06865 1/20 0.31
HEXB P07686 1/20 0.31
MCL1 Q07820 1/20 0.31
TBXAS1 P24557 1/20 0.30
CYP4F2 P78329 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29428571 1.00 HTR2A (0.37) HTR2AMEN1KMT2ATAAR1ALDH1A1
SCHEMBL23043210 0.95 HTR2A (0.38) HTR2AMEN1KMT2ATAAR1ALDH1A1
SCHEMBL23043093 0.87 HTR2A (0.40) HTR2AMEN1KMT2ATAAR1ALDH1A1
SCHEMBL29876215 0.87 HTR2A (0.40) HTR2AMEN1KMT2ATAAR1ALDH1A1
SCHEMBL28240529 0.82 LIPG (0.43) MCL1
SCHEMBL23043471 0.80 TAAR1 (0.38) HTR2AMEN1KMT2ATAAR1ALDH1A1
SCHEMBL25325280 0.80 TLR8 (0.39) HTR2ATAAR1CYP2D6MCL1
SCHEMBL3028718 0.79 TAAR1 (0.54) TAAR1ALDH1A1TSHRCA2MCL1
SCHEMBL1128764 0.79 CYP1A2 (0.36) HTR2AMEN1KMT2ATAAR1ALDH1A1
SCHEMBL9026542 0.77 TAAR1 (0.52) TAAR1ALDH1A1TSHRCA2MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216951-B1 KRAS G12D INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-04-01 EP disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
EP-4216951-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2023-08-02 EP disclosed
WO-2022066646-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357277-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS HTR2A 4855/4885MEN1 465/4885KMT2A 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.